Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘MDM2’

San Francisco F line Trolley originally from MilanSan Francisco – Acute Myeloid Leukemia (AML) is largely a disease of the elderly since it is uncommon before the age of 45. It generally has a much poorer prognosis compared to other leukemias such as CML and even ALL. There are two main treatment options – high chemotherapy (ara-C is the main bedrock) or a stem cell transplant in those patients who are considered eligible. With the average age at diagnosis being ~66yo, many patients may be elderly and frail, making a SCT not a viable option.

Ara-C (cytarabine) has been around for many years and despite numerous clinical trials, it has yet to be displaced. There’s plenty of room for improvement though, and a high unmet medical need still exists. The good news is that despite the challenge of finding a highly effective yet well tolerated therapy, there’s a lot of R&D activity in this space.

In this preview of the data to be presented at the American Society of Hematology (ASH) annual meeting in San Francisco, I highlight my top 10 AML abstracts that are worth checking out.

To learn more, you can sign in or sign up in the box below.

There are quite a few posters at the forthcoming AACR-NCI-EORTC Molecular Targets meeting this weekend that I wanted to highlight as potentially interesting and will additionally review in more depth once they have been published.

Please note: None of the embargoed abstracts are covered here in this preview to avoid any complications, but more detailed notes and reports will follow later on these from the conference as they are published.

Here some of the abstracts that caught my eye, in no particular order:

error: Content is protected !!